Hypertension and cognitive impairments: Possible mechanisms of development, diagnosis, and approaches to therapy

Zueva I.B.

doi:https://doi.org/10.17116/terarkh2015871296-100

Close metadata

Recommended articles:

Differentiated approach to cognitive rehabilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11

Clinical case of auricular gouty tophi. Russian Bulletin of Otorhinolaryngology. 2024;(6):80-84

Activation of endogenous mechanisms of sanogenesis in cognitive impairment in cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):7-13

Cognitive impairment in bilinguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29

Comprehensive rehabilitation of spinal trauma patients with extended involvement of nursing staff and neurometabolic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):93-98

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

The relationship between neuropsychological indicators and neuroimaging changes according to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152

Detection of mpox virus by enzyme immunoassay in a no-instrumental format and after its inactivation with formaldehyde. Molecular Genetics, Microbiology and Virology. 2024;(4):49-53

Laboratory diagnostics of monkeypox: basic methods and prospects for new developments. Laboratory Service. 2024;(4):57-64

Efficacy and tolerability of azilsartan combined with amlodipine and amlodipine monotherapy and combinations of amlodipine with other angiotensin II receptor blockers. Russian Cardiology Bulletin. 2024;(4-2):161-171

Abstract:

The review presents data on the role of hypertension in the development of cognitive impairments. It discusses issues of the early diagnosis of hypertension, the possibility of an integrated approach to therapy for cognitive disorders in hypertensive patients.

Keywords:

hypertension

cognitive impairments

diagnosis

therapy

cytoflavin

Authors:

Zueva I.B.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
St. Petersburg clinical scientific and practical center for specialized types of medical care, Saint-Petersburg, Russia

Close metadata

References:

MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-774.
Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. ActaNeuropathol. 2010;119(4):421-433. doi:10.1007/s00401-010-0654-5.
Nelson PT, Head E, Schmitt FA et al. Alzheimer’s disease is not «brain aging»: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571-187. doi:10.1007/s00401-011-0826-y.
Zueva I.B., Vanaeva K.I., Sanets E.L. i dr. Vzaimosvyaz' faktorov serdechnososudistogo riska s kognitivnymi funktsiyami u patsientov srednego vozrasta. Arterial'naya gipertenziya. 2011;17(5):432-441.
Barodka VM, Joshi BL, Berkowitz DE et al. Review article: implications of vascular aging. Anesth Analg. 2011;112(5):1048-1060. doi:10.1213/ane.0b013e3182147e3c.
Wimo A, Winblad B, Aguero-Torres H et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003;17(2):63-67.
Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-681.
Petrovitch H, White LR, Ross GW et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology. 2001;24;57(2):226-234.
Jakobsson E, Gaston-Johansson F, Ohlén J, Bergh I. Clinical problems at the end of life in a Swedish population, including the role of advancing age and physical and cognitive function. Scand J Public Health. 2008;36(2):177-182.
Ronnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord. 2011;31(6):460-466. doi:10.1159/000330020.
Laitala VS, Kaprio J, Koskenvuo M et al. Association and causal relationship of midlife obesity and related metabolic disorders with old age cognition. Curr Alzheimer Res. 2011;8(6):699-706.
Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol. 2001;64(6):575-611.
Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer’s disease. Neurobiol Aging. 2009;30(9): 1512-1514. doi:10.1016/j.neurobiolaging.2007.10.020.
Park L, Anrather J, Girouard H et al. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27(12):1908-1918.
Sojkova J, Beason-Held LL, Metter EJ. Intima-Media Thickness and Regional Cerebral Blood Flow in Older Adults. Stroke. 2010;41:273-279. doi:10.1161/strokeaha.109.566810.
Cabeza R, Nyberg L. Imaging cognition ii: An empirical review of 275 pet and fmri studies. J Cognitive Neuroscience. 2000;12:1-47.
Grady CL. Functional brain imaging and age-related changes in cognition. Biological Psychology. 2000;54:259-281.
Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta. 2012;1822(3):361-369. doi:10.1016/j.bbadis.2011.08.007.
Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press. 2011;20(5):274-283. doi:10.3109/08037051.2011.566246.
Fazekas F, Schmidt R, Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord. 1998;9(suppl 1):2-5.
Verhaaren BF, Vernooij MW, de Boer R et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension. 2013;61(6):1354-1359. doi:10.1161/hypertensionaha.111.00430.
Knopman DS, Penman AD, Catellier DJ et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology. 2011;76(22):1879-1885. doi:10.1212/wnl.0b013e31821d753f.
Raz N, Yang YQ, Rodrigue KM et al. White matter deterioration in 15 months: latent growth curve models in healthy adults. Neurobiol Aging. 2012;33(2):429.e1-5. doi:10.1016/j.neurobiolaging.2010.11.018.
Salat DH, Williams VJ, Leritz EC et al. Inter-individual variation in blood pressure is associated with regional white matter integrity in generally healthy older adults. Neuroimage. 2012;59(1):181-192. doi:10.1016/j.neurobiolaging.2010.11.018.
Polish J. Meta-analysis of P300 normative aging studies. Psychophysiology. 1996;33:1001-1003.
Gnezditskii V.V. Vyzvannye potentsialy mozga v klinicheskoi praktike. M.; 2003.
Gordeev S.A. Primenenie metoda endogennykh svyazannykh s sobytiyami potentsialov mozga R300 dlya issledovaniya kognitivnykh funktsii v norme i klinicheskoi praktike. Fiziologiya cheloveka. 2007;2:121-133.
Muscoso EG, Costanzo E, Daniele O et al. Auditory event-related potentials in subcortical vascular cognitive impairment and Alzheimer’s disease. J Neural Transm. 2006;113:1779-1786.
Sachs G, Anderer P, Margreiter N et al. P300 event-related potentials and cognitive function in social phobia. Psychiat Res. 2004;131:249-261.
Zueva I.B., Vanaeva K.I., Sanets E.L. Kognitivnyi vyzvannyi potentsial R300: Rol' v otsenke kognitivnykh funktsii u bol'nykh s arterial'noi gipertenziei i ozhireniem. Byulleten' VSNTsSO RAMN. 2012:32(5):55-62.
Shlyakhto E.V., Zueva I.B. Vliyanie terapii blokatorami retseptorov k angiotenzinu II na razvitie kognitivnykh rasstroistv u bol'nykh arterial'noi gipertenziei: rezul'taty issledovaniya OSCAR. Arterial'naya gipertenziya. 2010:16(2): 219-222.
Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
Ivnitskii Yu.Yu., Golovko A.I., Sofronov G.A. Yantarnaya kislota v sisteme sredstv metabolicheskoi korrektsii funktsional'nogo sostoyaniya i rezistentnosti organizma. SPb; 1998.
Kondrashova M.N., Kaminskii Yu.G., Maevskii E.I. Yantarnaya kislota v meditsine, pishchevoi promyshlennosti, sel'skom khozyaistve. Pushchino: ONTIAMN; 1996.
Romantsov M.G. Eksperimental'noe izuchenie preparatov na osnove yantarnoi kisloty — potentsial'noe primenenie v klinike. SPb.; 2001.
Belova L.A., Kolotik-Kameneva O.Yu., Mashin V.V. i soavt. Effektivnost' energokorrektora tsitoflavina pri lechenii bol'nykh gipertonicheskoi entsefalopatiei. Terapevticheskii arkhiv. 2014;9:65-70.
Belova L.A., Mashin V.V., Kolotik-Kameneva O.Yu., Proshin A.N. Vliyanie terapii Tsitoflavinom na funktsiyu endoteliya i tserebral'nuyu gemodinamiku u bol'nykh gipertonicheskoi entsefalopatiei. Antibiotiki i khimioterapiya. 2014;59:7-8.
Kartashova E.A., Romantsov M.G., Sarvilina I.V. Vliyanie tsitoflavina na molekulyarnye mekhanizmy razvitiya gipertenzivnoi entsefalopatii u patsientov s sistolicheskoi arterial'noi gipertenziei. Eksperimental'naya i klinicheskaya farmakologiya. 2014;77(6):18-23.
Olsen J, Blagoev B, Gnad F et al. Cell. 2006;127(3):633-648.
Raines Al, Nagdas S, Kerber M, Cheney R. Headless Myo10 is a negative regulator of full-length Myo10 and inhibits axon outgrowth in cortical neurons. J Biol Chem. 2012;287(30):24873-24883. doi:10.1074/jbc.m112.369173.
Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61(9):915-922. doi:10.1002/iub.234.
Holmes K, Roberts O, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10): 2003-2012.
Karthikeyan S, Leung T, Ladias JJ. Structural determinants of the Na+/H+ exchanger regulatory factor interaction with the beta 2 adrenergic and platelet-derived growth factor receptors. Biol Chem. 2002;277(21):18973-18978.
Vodop'yanova O.A., Moiseeva I.Ya., Rodina O.P. i dr. Vliyanie tsitoflavina i kardioksipina na pokazateli sutochnogo monitorirovaniya arterial'nogo davleniya u patsientov s khronicheskoi nedostatochnost'yu mozgovogo krovoobrashcheniya na fone arterial'noi gipertonii i giperkholesterinemii. Klinicheskaya meditsina. 2015;93(2):67-71.